Headlines about Athenex (NASDAQ:ATNX) have trended somewhat negative on Wednesday, Accern Sentiment reports. Accern identifies negative and positive press coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Athenex earned a media sentiment score of -0.01 on Accern’s scale. Accern also assigned media stories about the company an impact score of 45.551337455626 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
Several brokerages have recently weighed in on ATNX. BidaskClub raised Athenex from a “hold” rating to a “buy” rating in a research report on Wednesday. Needham & Company LLC initiated coverage on Athenex in a research note on Tuesday, March 6th. They set a “buy” rating and a $30.00 price target on the stock. JPMorgan Chase & Co. raised their price target on Athenex from $22.20 to $23.00 and gave the stock a “neutral” rating in a research note on Wednesday, January 24th. Finally, Deutsche Bank set a $20.00 price target on Athenex and gave the stock a “buy” rating in a research note on Wednesday, January 17th. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $28.17.
Athenex (ATNX) traded up $0.29 during trading hours on Wednesday, reaching $16.75. The company had a trading volume of 487,204 shares, compared to its average volume of 361,636. The stock has a market cap of $1,050.00 and a P/E ratio of -6.07. Athenex has a 12-month low of $11.21 and a 12-month high of $20.79.
ILLEGAL ACTIVITY NOTICE: “Athenex (NASDAQ:ATNX) Receiving Somewhat Critical Media Coverage, Analysis Finds” was first reported by StockNewsTimes and is the property of of StockNewsTimes. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of United States and international copyright and trademark legislation. The correct version of this piece of content can be accessed at https://stocknewstimes.com/2018/03/14/somewhat-critical-press-coverage-somewhat-unlikely-to-affect-athenex-atnx-share-price.html.
Athenex, Inc is an oncology pharmaceutical company focused on the development and commercialization of therapies for cancer diseases and supportive therapies. The Company’s technology platform is organized into three categories, including Oral Absorption Platform, Src Kinase Inhibitors and Symptom Therapeutics.
Receive News & Ratings for Athenex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athenex and related companies with MarketBeat.com's FREE daily email newsletter.